ODRC Enterprises, LLC dba Oregon Dermatology and Research Center
Welcome,         Profile    Billing    Logout  
 2 Trials 
6 Trials

   Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Rich, Phoebe
TOGETHER-PsO, NCT06588283: Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Recruiting
3
250
US
Ixekizumab, LY2439821, Tirzepatide, LY3298176
Eli Lilly and Company
Psoriasis, Obesity
12/25
05/26
NCT05135910: To Evaluate Hallux Terbinafine Subungual Gel (HSG) in the Treatment of Onychomycosis

Active, not recruiting
2a
35
US
Hallux Terbinafine Subungual Gel, HSG
Hallux, Inc.
Onychomycosis of Toenail
09/24
09/24
NCT05802173: Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

Completed
2
71
US
TDM-105795, 0.0025%, TDM-105795, 0.02%, TDM-105795 topical vehicle solution
Technoderma Medicines Inc., Therapeutics, Inc.
Alopecia, Androgenetic
11/23
01/24
NCT06176768: A Study of LY3972406 in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Recruiting
2
75
US
LY3972406, Placebo
Eli Lilly and Company
Plaque Psoriasis
04/25
07/25
NCT06108024: A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis

Recruiting
2
60
US
SM-020 gel 1.0%, Vehicle gel
DermBiont, Inc.
Seborrheic Keratosis
09/24
10/24
NCT05911841: A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Recruiting
2
260
Europe, Canada, Japan, US, RoW
LY3454738, Placebo
Eli Lilly and Company
Atopic Dermatitis
06/25
03/26

Download Options